[Contraception and thrombophilia].

La Revue du praticien Pub Date : 2025-03-01
Geneviève Plu-Bureau, Brigitte Raccah-Tebeka
{"title":"[Contraception and thrombophilia].","authors":"Geneviève Plu-Bureau, Brigitte Raccah-Tebeka","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>CONTRACEPTION AND THROMBOPHILIA. The term thrombophilia includes two different aspects to be considered: the biological aspect with the existence of a hemostasis anomaly activating coagulation and increasing the risk of venous thromboembolic event (VTE), and the clinical aspect with the existence of a first-degree relative having had a venous thromboembolic event at a young age. Systematic screening for biological thrombophilia is not recommended before prescribing hormonal contraception in the absence of a family history or personal event, as it is probably not cost-effective. All combined hormonal contraceptives, whatever the route of administration (oral, patch or vaginal ring) or type of estrogen, are contraindicated in women with biological thrombophilia. Injectable progestin contraception with medroxyprogesterone acetate is also contraindicated. All other contraceptives strategies are authorized: copper or levonorgestrel intrauterine devices (IUD), progestin-only pills, subcutaneous implants, definitive contraception in the case of a completed parental project.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"290-292"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue du praticien","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

CONTRACEPTION AND THROMBOPHILIA. The term thrombophilia includes two different aspects to be considered: the biological aspect with the existence of a hemostasis anomaly activating coagulation and increasing the risk of venous thromboembolic event (VTE), and the clinical aspect with the existence of a first-degree relative having had a venous thromboembolic event at a young age. Systematic screening for biological thrombophilia is not recommended before prescribing hormonal contraception in the absence of a family history or personal event, as it is probably not cost-effective. All combined hormonal contraceptives, whatever the route of administration (oral, patch or vaginal ring) or type of estrogen, are contraindicated in women with biological thrombophilia. Injectable progestin contraception with medroxyprogesterone acetate is also contraindicated. All other contraceptives strategies are authorized: copper or levonorgestrel intrauterine devices (IUD), progestin-only pills, subcutaneous implants, definitive contraception in the case of a completed parental project.

[避孕和血栓形成]。
避孕和血栓症。血栓病这个术语包括两个不同的方面需要考虑:生物学方面,存在一种止血异常,激活凝血,增加静脉血栓栓塞事件(VTE)的风险;临床方面,存在一种一级亲属在年轻时发生过静脉血栓栓塞事件。在没有家族史或个人事件的情况下,不建议在开具激素避孕处方之前对生物血栓形成进行系统筛查,因为这可能不具有成本效益。所有的联合激素避孕药,无论是何种给药途径(口服、贴片或阴道环)或雌激素类型,都是生物性血栓形成症女性的禁忌症。注射黄体酮避孕与醋酸甲孕酮也是禁忌。所有其他避孕策略均被批准:铜或左炔诺孕酮宫内节育器(IUD),孕激素单药,皮下植入,在完成父母项目的情况下确定避孕。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信